Accessibility Menu
 
Innoviva logo

Innoviva

(NASDAQ) INVA

Current Price$22.62
Market Cap$1.68B
Since IPO (2004)+67%
5 Year+90%
1 Year+27%
1 Month-7%

Innoviva Financials at a Glance

Market Cap

$1.68B

Revenue (TTM)

$414.76M

Net Income (TTM)

$271.17M

EPS (TTM)

$3.06

P/E Ratio

7.42

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Price

$22.62

Volume

13,853

Open

$22.70

Previous Close

$22.62

Daily Range

$22.54 - $23.16

52-Week Range

$16.52 - $25.14

INVA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innoviva

Industry

Pharmaceuticals

Employees

159

CEO

Pavel Raifeld, CFA, MBA

Headquarters

Burlingame, CA 94010, US

INVA Financials

Key Financial Metrics (TTM)

Gross Margin

79%

Operating Margin

-4%

Net Income Margin

65%

Return on Equity

29%

Return on Capital

-1%

Return on Assets

17%

Earnings Yield

13.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.68B

Shares Outstanding

74.07M

Volume

13.85K

Short Interest

0.00%

Avg. Volume

751.84K

Financials (TTM)

Gross Profit

$307.52M

Operating Income

$163.75M

EBITDA

$383.79M

Operating Cash Flow

$196.93M

Capital Expenditure

$1.13M

Free Cash Flow

$195.80M

Cash & ST Invst.

$550.94M

Total Debt

$269.02M

Innoviva Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$118.05M

+28.6%

Gross Profit

$75.61M

-10.7%

Gross Margin

64.05%

N/A

Market Cap

$1.68B

N/A

Market Cap/Employee

$13.22M

N/A

Employees

127

N/A

Net Income

$164.15M

+707.4%

EBITDA

$208.47M

+479.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$281.92M

+830.4%

Accounts Receivable

$34.97M

-59.5%

Inventory

$39.17M

+16.2%

Long Term Debt

$268.60M

+4.3%

Short Term Debt

$418.00K

-99.8%

Return on Assets

16.58%

N/A

Return on Invested Capital

-1.05%

N/A

Free Cash Flow

$53.38M

-3.4%

Operating Cash Flow

$54.51M

-8.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLAYRelay Therapeutics, Inc.
$9.60-5.14%
NKTRNektar Therapeutics
$68.66-3.25%
SNDXSyndax Pharmaceuticals, Inc.
$23.49-4.90%
IMTXImmatics N.V.
$9.37-4.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$167.52-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%

Questions About INVA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.